



FILING RECEIPT



OC000000005341449

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/580,281	05/30/2000	1614	834	PC8605C KKK _		28	3

Paul H Ginsburg
Pfizer Inc
20th Floor
235 East 42nd Street
New York, NY 10017-5755

Date Mailed: 08/22/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Yuhpyng L. Chen, Residence Not Provided;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 08/741,066 10/30/1996
AND A CIP OF 09/254,387 03/04/1999

Foreign Applications

If Required, Foreign Filing License Granted 07/24/2000

Title

Corticotropin releasing factor antagonists

Preliminary Class

514

Data entry by : SHIFERAW, MESERET

Team : OIPE

Date: 08/22/2000

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

RECEIVED
AUG 30 2000
PFIZER INC.
PATENT DEPT.-NYO



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231



Receipt

Applicant's Docket No. U-014294-1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yuhpyng L. CHEN

Serial No.: 09/580,281

Group No.: 1614

Filed: May 30, 2000

Examiner: D. Jones

For: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

[X] incorrectly entered

and/or

[] omitted.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8a)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

- ☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

FACSIMILE

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: November 18, 2002

Signature

JOHN RICHARDS

(type or print name of person certifying)

<i>Error in</i>	<i>Correct data</i>
1. [] Applicant's name	1.
2. [] Applicant's address	2.
3. [] Title	3.
4. [] Filing Date	4.
5. [] Serial Number	5.
6. [] Foreign/PCT Application Re:	6.
7. [X] Other ATTORNEY DOCKET NO.	7. Delete "PC8605C" and Insert -- U-014294-1--


SIGNATURE OF PRACTITIONER

JOHN RICHARDS
(Type or print name of practitioner)

P.O. Address
c/o Ladas & Parry
26 West 61 Street
New York, NY 10023

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

Reg. No. 31,053

Tel. No.: (212) 708-1915

Customer No. 00140



FILE COPY

Commissioner for Patents
Washington, DC 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 1660

SERIAL NUMBER 09/580,281	FILING DATE 05/30/2000 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. U-014294-1	
APPLICANTS Yuhpyng L. Chen, Waterford, CT;					
** CONTINUING DATA ***** This application is a CIP of 08/741,066 10/30/1996 PAT 6,403,599 and is a CIP of 09/254,387 03/04/1999 PAT 6,316,631					
** FOREIGN APPLICATIONS *****					
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 07/24/2000					
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged <i>[Signature]</i> Examiner's Signature Initials		STATE OR COUNTRY CT	SHEETS DRAWING	TOTAL CLAIMS 28	INDEPENDENT CLAIMS 3
ADDRESS Ladas & Parry 26 West 61st Street New York, NY 10023					
TITLE Corticotropin releasing factor antagonists					
FILING FEE RECEIVED 964	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yuhpyng L. CHEN

Serial No.: 09/580,281

Group No.: 1614

Filed: May 30, 2000

Examiner: D. Jones

For: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Attorney Docket No.: U-014294-1

Commissioner of Patents and Trademarks
Washington, DC 20231

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

Sir:

CORRESPONDENCE ADDRESS

Please direct all communication to:
Ladas & Parry
26 West 61st Street
New York, New York 10023

Respectfully submitted,



JOHN RICHARDS

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

☒ with sufficient postage as first class mail.

37 C.F.R. 1.10*

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Date: November 18, 2002



Signature

JOHN RICHARDS

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.